Insider · CIK 0001797157
Bridget E Karlin
director
Files at DAN (DANA Inc), LYB (LyondellBasell Industries N.V.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | LYB LyondellBasell Industries N.V. | AGrant or award Class A Ordinary Shares | +781 | $0.00 | $0 | 8,028 | 9 d ago |
| Sep 30, 2026 | LYB LyondellBasell Industries N.V. | FTax withholding Class A Ordinary Shares | -194 | $57.47 | $11k | 7,834 | 9 d ago |
| Aug 28, 2026 | DAN DANA Inc | AGrant or award Dividend Equivalent Rightsderivative | +21 | $0.00 | $0 | 60 | 39 d ago |
| Mar 21, 2025 | DAN DANA Inc | AGrant or award Dividend Equivalent Rightsderivative | +71 | $0.00 | $0 | 71 | Mar 21, 2025 |
| Feb 14, 2025 | DAN DANA Inc | MOption exercise Common Stock, par value $0.01 | +12,359 | $0.00 | $0 | 41,725 | Feb 19, 2025 |
| Feb 14, 2025 | DAN DANA Inc | MOption exercise Common Stock, par value $0.01 | +425 | $0.00 | $0 | 42,150 | Feb 19, 2025 |
| Feb 14, 2025 | DAN DANA Inc | MOption exercise Dividend Equivalent Rightsderivative | -425 | $0.00 | $0 | 0 | Feb 19, 2025 |
| Feb 14, 2025 | DAN DANA Inc | MOption exercise Restricted Stock Unitsderivative | -12,359 | $0.00 | $0 | 0 | Feb 19, 2025 |
| Feb 11, 2025 | DAN DANA Inc | AGrant or award Restricted Stock Unitsderivative | +10,104 | $0.00 | $0 | 10,104 | Feb 13, 2025 |
| Nov 29, 2024 | DAN DANA Inc | AGrant or award Dividend Equivalent Rightsderivative | +126 | $0.00 | $0 | 425 | Dec 2, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.